Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Preparing compound containing saccharide radical
Patent
1990-09-06
1993-07-27
Nucker, Christine M.
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Preparing compound containing saccharide radical
530329, 530328, 530327, 530326, 530325, 530324, G01N 33574, C07K 706, C07K 708, C07K 710
Patent
active
052310027
ABSTRACT:
The SCM (structuredness of cytoplasmic matrix) test is a means of distinguishing lymphocytes isolated from mammalian donors, including humans, afflicted with cancer from lymphocytes isolated from donors free of malignancy. The test comprises contacting the lymphocytes with a challenging agent and then observing a decrease in the structuredness of the cytoplasmic matrix in lymphocyte from donors with cancer; lymphocytes from donors without cancer show no decrease in structuredness. Preferably the decrease in structuredness is quantified by measuring the fluorescence polarization for an extrinsic fluor added to the cells and observing a decrease in fluorescence polarization after lymphocytes from a donor with cancer have been contacted with a challenging agent. Among the challenging agents useful in the SCM test are several synthetic peptides which are the subject of the present invention. These peptides, of which two have the amino acid sequences Phe-Trp-Gly-Ala-Gly-Gln-Arg (I) and Phe-Trp-Gly-Ala-Glu-Gly-Gln-Arg (II), react with lymphocytes from donors with any type of malignancy. Also among the aspects of the present invention are several other peptides expected to have SCM activity because of their close structural relationship to peptides I and II, methods of using the synthetic SCM-active peptides in tests for the presence or absence of malignancy, antibodies specifically binding the synthetic peptides, including monoclonal antibodies, and genetic probes consisting of DNA sequences corresponding to the amino acid sequences of the synthetic SCM-active peptides.
REFERENCES:
patent: 4038282 (1977-07-01), Hirschmann et al.
patent: 4657892 (1987-04-01), Brantl
Whitham et al., Biochem J. 240, 913-916 (1986).
A. A. Gershkovich, V. K. Kibirev, S. B. Serebryanyi, Ya. T. Terletskaya, E. P. Kozulina, & Ya. V. Belik, "A Study of the Properties of Synthetic Analogs of the Tryptophan-Containing Fragment 113-121 of the Basic Protein of Myelin," Khimiya Prirodnykh Soedinenii 4, 557-565 (1979) (translated from Russian).
S. Levit, J. M. Powers, D. Milek, & S. W. Brostoff, "Peptide Length Requirement for Experimental Allergic Encephalomyelitis in Guinea Pigs," Neurochem. Res. 5, 37-42 (1980).
Suzuki et al., "Studies on Encephalitogenic Fragments of Myelin Protein . . . ", Chem Pharm. Bull. 22(9), 2181-2187 (1974).
Deber et al., "Association of Carbon-13 Enriched Human Encephalitogenic Nonapeptide . . . ", J. Biol. Chem 254(14), 6341-45 (1979).
L. Cercek, B. Cercek, C. I. V. Franklin, "Biophysical Differentiation Between Lymphocytes from Healthy Donors, Patients with Malignant Diseases and Other Disorders," Brit. J. Cancer 29, 345-352 (1974).
L. Cercek & B. Cercek, "Application of the Phenomenon of Changes in the Structuredness of Cytoplasmic Matrix (SCM) in the Diagnosis of Malignant Disorders: a Review," Europ. J. Cancer 13, 903-915 (1977).
L. Cercek & B. Cercek, "Changes in SCM-Responses of Lymphocytes in Mice After Implantation with Ehrlich Ascites Cells," Europ. J. Cancer 17, 167-171 (1981).
L. Cercek & B. Cercek, "Changes in the SCM Response Ratio (RR.sub.SCM) After Surgical Removal of Malignant Tissue," Brit. J. Cancer 31, 250-251 (1975).
L. Cercek & B. Cercek, "Apparent Tumour Specificity with the SCM Test," Brit. J. Cancer 31, 252-253 (1975).
Spinco Brochure DS-404, "Experimental Allergic Encephalitogenic Peptide (Human)".
R. B. Wallace, M. J. Johnson, T. Hirose, T. Miyake, E. H. Kawashima, & K. Itakura, "The Use of Synthetic Oligonucleotides as Hybridization Probes. II. Hybridization of Oligonucleotides of Mixed Sequence to Rabbit-Globin DNA," Nucl. Acids Res., 9, 879-894 (1981).
R. Lathe, "Snythetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data: Theoretical and Practical Considerations," J. Mol. Biol. 183, 1 (1985).
M. Deutsch & A. Weinreb, "Validation of the SCM-Test for the Diagnosis of Cancer," Eur. J. Cancer Clin. Oncol. 19, 187-193 (1983).
Cercek Boris
Cercek Lea
Nucker Christine M.
Woodward M. P.
LandOfFree
Synthetic SCM-active cancer recognition peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthetic SCM-active cancer recognition peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic SCM-active cancer recognition peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2341766